Monday, December 31, 2018 2:10:57 PM
What's speculative about my points that you agree with. LP 7 co worked for 10+ years to discover/create/validate the mechanisms, processes and methods to make DCVax viable. That's not speculative, it's fact. When most BPs abandoned Dendritic Cell Vaccines, LP was hard at work...and still is. again, fact!
Stop the gibberish and answer the question: So why do you make accusations 24/7 against LP & NWBO?
Because, it is all just speculative, as is a BO by H...until proven otherwise. Let’s hope they announce a ASM, and not conference call, and this doesn’t go until 2020 to announce as some here are speculating...GLTUA-- Ultraz2
Ultraz2, I am glad you agree with my points:
LP & company worked for 10+ years to discover/create/validate the mechanisms, processes and methods to make DCVax viable and everyone realize the potential disruption in the pharmaceutical industry. Everyone is trying to jump on the bandwagon. But, IMHO, Linda may have created a barrier of entry by extending the trial, increasing the results-- assuming of course dcvax-l is approved.
instead of ragging on Lp/NWBO managment 24/7 give credit were credit is due. When most BPs abandoned Dendritic Cell Vaccines, LP was hard at work...and still is. A "thank you" would be appropriate.
So why do you make these posts 24/7?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145723802
I’m very surprised this isn’t a sub penny stock at this point. I really believe there is a big chance L will never see approval...especially since LP now has even more millions to take out of the company for her own private interests...she can’t keep this company afloat once this money runs out this time. I think the end of this long journey is rapidly approaching...I just feel terrible it appears LL’s work has been so poorly managed by these people...we will see, good or bad, very soon...I imagine, once the check is in the mail. This has been one self-serving disaster that is truly circling the drain imho.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145729573
...I’ve have been investing in the market for 30 years, in biotech, have never seen such a blatant disregard for investors and self-serving manipulation...seriously...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145766441
I just don’t understand how the SEC allows this to continue if never unblinded, or unblinded, and PFS FAILED YEARS AGO and they knew about it and didn’t disclose it to investors.
Wholeheartedly agree...Ultraz
This drug is in phase one testing. Other drugs in the pipeline are either in pre-phase-1 development, in phase-1 or just completing phase 1. During phase 1 everything looks promising as testing is primarily concerned with safety. Only after phase 2, will there be any info one can base an investment decision on.
There are bunch of small startup bios that are now testing Dendritic Cell Vaccines. Why is that? It could be because the L P& company worked for 10+ years to discover/create/validate the mechanisms, processes and methods to make DCVax viable and everyone realize the potential disruption in the pharmaceutical industry. Everyone is trying to jump on the bandwagon. But, IMHO, Linda may have created a barrier of entry by extending the trial, increasing the results-- assuming of course dcvax-l is approved.
So, perhaps you may want to, instead of ragging on Lp/NWBO management 24/7 give credit were credit is due. When most BPs abandoned Dendritic Cell Vaccines, LP was hard at work...and still is. A "thank you" would be appropriate.
Recent NWBO News
- How Advanced Drug Delivery Could Improve Existing Cancer Treatments • GlobeNewswire Inc. • 06/01/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
| Volume | |
| Day Range: | |
| Bid Price | |
| Ask Price | |
| Last Trade Time: |
